Immature Acta2R179C/+ smooth muscle cells cause moyamoya-like cerebrovascular lesions in mice prevented by boosting OXPHOS

Nat Commun. 2025 Jul 2;16(1):6105. doi: 10.1038/s41467-025-61042-3.

Abstract

ACTA2 pathogenic variants altering arginine 179 cause childhood-onset strokes due to moyamoya disease (MMD)-like occlusions of the distal internal carotid arteries, but the mechanisms of pathogenesis are unknown and no preventive treatments exist. Here we show that Acta2R179C/+ smooth muscle cells (SMCs) fail to fully differentiate and maintain stem cell-like features, including increased migration and glycolytic flux compared to wildtype (WT) SMCs. Increasing mitochondrial respiration with nicotinamide riboside (NR) drives differentiation and decreases migration of Acta2R179C/+ SMCs. Carotid artery injury of Acta2SMC-R179C/+ mice leads to premature death, intraluminal SMC accumulation leading to MMD-like occlusive lesions, neurologic symptoms, and neuron loss, whereas injured WT mice have none of these phenotypes, and all are prevented by NR treatment in the Acta2SMC-R179C/+ mice. These data show that driving differentiation and quiescence of Acta2R179C/+ SMCs by altering cellular metabolism attenuates MMD-like disease in the Acta2SMC-R179C/+ mice, highlighting a role of immature and highly migratory SMCs in the pathogenesis of MMD.

MeSH terms

  • Actins* / genetics
  • Actins* / metabolism
  • Animals
  • Cell Differentiation / drug effects
  • Cell Movement / drug effects
  • Disease Models, Animal
  • Female
  • Glycolysis
  • Humans
  • Male
  • Mice
  • Mice, Inbred C57BL
  • Mitochondria / metabolism
  • Moyamoya Disease* / genetics
  • Moyamoya Disease* / metabolism
  • Moyamoya Disease* / pathology
  • Muscle, Smooth, Vascular
  • Myocytes, Smooth Muscle* / drug effects
  • Myocytes, Smooth Muscle* / metabolism
  • Myocytes, Smooth Muscle* / pathology
  • Niacinamide / analogs & derivatives
  • Niacinamide / pharmacology
  • Oxidative Phosphorylation* / drug effects

Substances

  • Actins
  • Acta2 protein, mouse
  • Niacinamide

Grants and funding